Big Data isn't just about the datacentre. Data architecture, data processing and data management are all important. That's according to Alan Priestley, director of strategic marketing EMEA for Intel, who was addressing the audience at ...
Tags: Computer Products, software
Businesses need to stop "pouring money" into big data storage hardware and software acquisitions, and spend resources on insight and interpretation, Autonomy has warned at today's Computing Big Data Summit. In a reimagining of ROI that ...
Tags: Computer Products, software
AstraZeneca is set to establish a global research and development (R&D) center at Gaithersburg, Maryland to improve pipeline productivity. These changes are made in order to simplify the company's global site footprint and to invest in ...
Tags: AstraZeneca, R&D center, research and development center
MaRS Discovery District—an innovation centre located in Toronto, Ont.—has appointed Elyse Allan, president and CEO of GE Canada to its board of directors. (Also appointed was Elaine Campbell, president of AstraZeneca Canada ...
Tags: MaRS Discovery District, Elyse Allan, strategic objectives
UK-based pharmaceutical company Bristol-Myers Squibb and AstraZeneca have announced that the National Institute for Health and Clinical Excellence (NICE) in the UK has issued an Appraisal Consultation Document (ACD) for its first-in-class, ...
Tags: pharmaceutical company, Bristol-Myers Squibb, AstraZeneca, NICE
Only 8% of European companies plan to decrease spending on antivirus and antimalware in 2013, a survey of IT security purchasing intentions has revealed. Some 21% of more than 250 IT professionals polled by Computer Weekly and TechTarget ...
Tags: European companies, antivirus, IT security, TechTarget
Cybergeddon, a complete take-down of the internet, is undoubtedly within the power of some nation states, but is unlikely, say security industry experts. Bringing down the internet would not be in anyone’s interest, said Fred Piper, ...
Tags: Cybergeddon, internet, security industry, security consulting
The US FDA has approved Mylan Pharmaceuticals' abbreviated new drug application (ANDA) for generic Atacand HCT tablets to treat hypertension. Candesartan Cilexetil and Hydrochlorothiazide Tablets in 16/12.5mg, 32/12.5mg and 32/25mg ...
Tags: US FDA, hypertension medication, ANDA, hypertension
AstraZeneca and US Food and Drug Administration (FDA) have agreed to update label for Faslodex (fulvestrant) injection. The updated prescribing information for Faslodex US contains results and a Kaplan-Meier plot of the final overall ...
Tags: AstraZeneca, Faslodex injection label, US, FDA
Biopharmaceutical company AstraZeneca has announced agreement with the US Food and Drug Administration (FDA) with regard to FASLODEX (fulvestrant) Injection label changes. The labeling update includes results and a Kaplan-Meier plot of ...
Tags: FASLODEX Injection label, AstraZeneca, prescription medicines
Thomson Reuters' Intellectual Property & Science division has launched a new mobile oncology decision support solution to support R&D focused pharmaceutical majors. The solution provides a series of oncology-based clinical dashboards that ...
Tags: Thomson Reuters, new mobile oncology decision support solution
Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or a total buying price nearing $5.3bn. The acquisition value includes Amylin's debt proceeds and a contractual ...
AstraZeneca and Ardelyx have signed a worldwide exclusive licensing agreement for Ardelyx's NHE3 inhibitor programme for the treatment of complications associated with end-stage renal disease (ESRD) and chronic kidney disease (CKD). The ...
Tags: RDX5791, Ardelyx, AstraZeneca, NHE3 inhibitor programme, NHE3
Dr. Reddy's Laboratories, an integrated global pharmaceutical company, has introduced Metoprolol Succinate extended-release (ER) tablets of 25mg, 50mg, 100mg and 200mg strengths in the US. The bioequivalent generic version of ...
Tags: Toprol-XL, metoprolol succinate, ER
Pharmaron has signed a multi-year agreement with AstraZeneca to accelerate drug discovery by supporting the Medicines Units. Pursuant to the agreement, Pharmaron will offer discovery services in the areas of chemistry, drug metabolism and ...
Tags: drug discovery, medicines, chemistry, drug metabolism, pharmacokinetics